{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-328684","form_type":"8-K/A","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.496501+00:00","generated_at":"2026-05-16T12:24:22.827824+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silence Therapeutics discloses interim CEO pay and new director committee roles","bullets":["Interim CEO Iain Ross receives £25,000/month cash for six months, then month-to-month, plus 900,000 option shares vesting over 12 months.","New director James Ede-Golightly appointed to Remuneration, Audit & Risk, and Nominations Committees; granted 90,000 option shares vesting over 12 months.","Ross is also eligible for a discretionary cash bonus as determined by the Remuneration Committee.","Both option grants are under the company's 2023 Equity Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-328684","json":"https://secwatch.observer/filing/0001193125-25-328684.json","markdown":"https://secwatch.observer/filing/0001193125-25-328684.md","text":"https://secwatch.observer/filing/0001193125-25-328684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525328684/0001193125-25-328684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525328684/sln-20251214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:24:22.827824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}